In silico insight into EGFR treatment in patients with lung carcinoma and T790M mutations

The T790M mutational basis of treatment failure, following treatment via alteration of the epidermal growth factor receptor (EGFR) pathway, is a well-known anomaly in patients with non-small cell lung cancer (NSCLC). The T790M mutation activates the kinase domain, causing tyrosine kinase inhibitors,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Shu-Zhi, Yang, Yan-Rong, Zhao, Sha-Sha, Li, Yun-Xia, Gao, Xin-Yuan, Zhong, Chun-Lei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443239/
https://www.ncbi.nlm.nih.gov/pubmed/28565760
http://dx.doi.org/10.3892/etm.2017.4168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5443239/
https://www.ncbi.nlm.nih.gov/pubmed/28565760
http://dx.doi.org/10.3892/etm.2017.4168

Ejemplares similares